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Abstract
Background: In the US, an unacceptably high percentage of pregnant women do not undergo prenatal HIV testing.
Previous studies have found increased uptake of prenatal HIV testing with abbreviated pre-test counseling, however little is
known about patient decision making, testing satisfaction and knowledge in this setting.
Methodology/Findings: A randomized-controlled, non-inferiority trial was conducted from October 2006 through February
2008 at San Francisco General Hospital (SFGH), the public teaching hospital of the City and County of San Francisco. A total of
278 English- and Spanish-speaking pregnant women were randomized to receive either abbreviated or standard nurse-
performed HIV test counseling at the initial prenatal visit. Patient decision making experience was compared between
abbreviated versus standard HIV counseling strategies among a sample of low-income, urban, ethnically diverse prenatal
patients. The primary outcome was the decisional conflict score (DCS) using O’Connor low-literacy scale and secondary
outcomesincludedsatisfactionwithtestdecision,basicHIVknowledgeandHIVtestinguptake.Weconductedanintention-to-
treat analysis of 278 women – 134 (48.2%) in the abbreviated arm (AA) and 144 (51.8%) in the standard arm (SA). There was no
significant difference in the proportion of women with low decisional conflict (71.6% in AA vs. 76.4% in SA, p=.37), and the
observed mean difference between the groups of 3.88 (95% CI: 20.65, 8.41) did not exceed the non-inferiority margin. HIV
testing uptake was very high (97. 8%) and did not differ significantly between the 2 groups (99.3% in AA vs. 96.5% in SA,
p=.12). Likewise, there was no difference in satisfaction with testing decision (97.8% in AA vs. 99.3% in SA, p=.36). However,
women in AA had significantly lower mean HIV knowledge scores (78.4%) compared to women in SA (83.7%, p,0.01).
Conclusions/Significance: This study suggests that streamlining the pre-test counseling process, while associated with
slightly lower knowledge, does not compromise patient decision making or satisfaction regarding HIV testing.
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Introduction
Approximately 40% of HIV-infected infants in the United
States in 2000 were born to women not diagnosed with their HIV
prior to delivery. [1] There are now effective medical therapies to
dramatically reduce the risk of perinatal transmission, including
anti-retroviral therapy, but this intervention is most effective when
women are diagnosed prior to delivery. The Centers for Disease
Control and Prevention (CDC), United States Preventive Services
Task Force and Institute of Medicine (IOM) have published strong
recommendations for universal HIV-antibody testing of pregnant
women. [2–5] A recent meta-analysis also demonstrated strong
evidence supporting routine prenatal HIV testing. [4]
There are currently two common testing strategies. In an opt-
out approach, all women are informed of the inclusion of HIV
testing in the standard battery of prenatal labs and may decline
such testing. On the other hand, standard, opt-in strategies use
more traditional voluntary HIV counseling and testing techniques,
which typically include pre-test counseling and/or risk assessment.
In a recent CDC retrospective analysis, prenatal HIV testing
uptake differed widely according to testing strategy used in various
regions in the United States and Canada.[3] Prenatal HIV testing
was most common in areas with an opt-out approach, with up to
98% of pregnant women testing. In regions using an opt-in
approach, testing frequencies were as low as 25%. In September
2006, the CDC published revised recommendations for HIV
testing in US healthcare settings. [6] In addition to recommending
routine, opt-out prenatal HIV screening, the authors advocated
streamlined consenting with removal of requirements for preven-
tion counseling as part of screening and diagnostic HIV testing
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5166procedures. While there are population-based studies and other
observational studies using historical controls [7] supporting
routine, opt-out HIV test counseling, little is known about patient
decision making, testing satisfaction and subsequent HIV
knowledge with abbreviated counseling.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of California San
Francisco and San Francisco General Hospital. All patients
provided written informed consent for the data collection and
subsequent analysis.
This was a randomized-controlled, non-inferiority trial evalu-
ating decisional conflict, HIV knowledge and testing uptake
associated with two HIV testing strategies among English and
Spanish-speaking pregnant women. The strategies included nurse-
performed, standard HIV pre-test counseling (control arm) and
abbreviated, pre-test counseling (study arm). The standardized
HIV pre-test counseling and consent process took approximately
2–5 minutes and reviewed the definition of HIV, modes of
transmission and prevention, interpretation of test results and the
benefits of testing. The intervention arm used a 2-sentence script
which lasted approximately 30 seconds. See Appendix S1. We
hypothesized that decisional conflict and testing uptake would not
differ significantly among women in the abbreviated study arm
and standard control arm.
Eligible participants included English and Spanish -speaking
women aged 16 or older initiating prenatal care at San Francisco
General Hospital (SFGH) between October 3, 2006 and
September 24, 2007. Women were considered ineligible if they
were unable to give informed consent, known to be infected with
HIV at initiation of prenatal care, or obtained an HIV test during
the index pregnancy prior to initiation of prenatal care at SFGH.
Research staff approached eligible women in the clinic
immediately before their initial appointment at the SFGH
Women’s Health Center. Study staff recruited and obtained
written informed consent from all participants and the UCSF
Committee on Human Research approved this study. Enrolled
participants were randomized to either the standard or abbrevi-
ated pre-test counseling strategy. At the onset of the prenatal
appointment, the intake nurse gave all pregnant women,
regardless of study enrollment, a low-literacy HIV educational
brochure to be read at a later time. During the appointment, the
nurse administered either the standard or abbreviated HIV pre-
test counseling script, documented the woman’s decision to take or
not take the HIV test and obtained written test consent or refusal
from the woman as per California state law at the time of the
study. Immediately following the appointment, blinded, bilingual
study staff administered a structured questionnaire to each
participant. The questionnaire included the 10-item O’Connor
Low-Literacy Decisional Conflict Scale (DCS), a 9-item instru-
ment assessing basic HIV knowledge (including HIV as the cause
of AIDS, perinatal and non-perinatal modes of transmission,
whether people with HIV always look and feel sick and whether
there is a cure for HIV), a scale assessing perceived risk of being
HIV positive, reasons for testing or not testing and satisfaction
with information received and the decision-making process. [8–10]
The O’Connor DCS was used in order to assess the level of
certainty and satisfaction with the patient’s decision to undergo or
not undergo HIV testing upon having received the nurse-
performed abbreviated or standard pre-test counseling. The scale
evaluates the extent to which patients feel informed about a
medical decision, whether the patients’ assessment of the relative
risks and benefits of each decision are consistent with their values,
whether patients have enough support and advice to make a
decision without pressure from others, and the certainty about the
decision. See Table 1. Upon the patients’ return for the follow-up
clinician visit, typically within 2–4 weeks, blinded study staff
administered a second survey following HIV test result disclosure
by the medical provider. The second survey included items
adapted from Simpson et al. and evaluated overall satisfaction
with the consent and results disclosure process as well as the
decision to undergo HIV testing. [10] See Appendix S2.
Randomization
Study staff generated the randomization scheme using random
number tables. HIV consenting scripts, each a single page and
identical in weight, were sequentially numbered by study staff and
sealed in opaque envelopes which were given to the nurse once the
patient consented to participate in the study. Group assignment
was not revealed to the study staff until after completion of the
study. While participants were informed during the study consent
process that they would receive either more or less pre-test
counseling, they were not specifically told about their respective
group assignment. The nurses were not blinded because they were
administering the appropriate script to the patients as per random
assignment.
Statistical methods
We compared differences between women in the control and
study arms, including the proportion of women with low decisional
conflict (DCS score#25), mean/median DCS scores, mean/
median knowledge scores, the proportion of women reporting
overall satisfaction with their decision regarding HIV testing and
the percentage of women undergoing HIV testing.
We measured decisional conflict, the primary outcome of the
study, using the English or Spanish-language Low-Literacy
Decisional Conflict Scale. [8,9] We calculated a score for all
study participants using the Low-Literacy Decisional Conflict
Table 1. O’Connor Low-Literacy Decisional Conflict Scale [13] *
Do you know which options are available to you?
Do you know the benefits of each option?
Do you know the risks and side effects of each option?
Are you clear about which benefits matter most to you?
Are you clear about which risks and side effects matter most to you?
Do you have enough support from others to make a choice?
Are you choosing without pressure from others?
Do you have enough advice to make a choice?
Are you clear about the best choice for you?
Do you feel sure about what to choose?
*All questions have 3 response categories: yes, no, unsure
Items are scored as 0=yes, 2=unsure, 4=no.
Scores for each of the 10 items are summed, divided by 2 and multiplied by 25
to calculate the total score.
doi:10.1371/journal.pone.0005166.t001
Pretest HIV Counseling Trial
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multiple languages. [11] As has been validated in other studies, we
considered a decisional conflict score of 25 or less to be low,
corresponding to limited conflict. [11,12] Other variables
measured included demographic characteristics, prior HIV testing
history, knowledge about HIV/AIDS, attitudes towards HIV
testing, type of provider (physician, midwife or nurse practitioner),
perceived risk of being HIV positive and reasons for testing or not
testing. We calculated a knowledge score as the percentage of
correct answers on the 9-item knowledge scale. We measured the
uptake of testing as a proportion of those in each arm who
underwent HIV testing. For binary variables, we compared
proportions between the 2 groups using the x
2 test or Fisher’s
exact Test. For continuous variables, we assessed for normal
distribution using the Kolmogorov-Smirnov test and used the
Wilcoxon-Mann Whitney test or Student’s T-test as appropriate.
A p-value less than 0.05 was considered statistically significant. To
assess non-inferiority with respect to the decisional conflict score,
we used a one-sided two group t-test of equivalence in means with
equal variances with an equivalence limit difference of 5.625. We
then evaluated DCS scores and knowledge scores, stratifying by
ethnicity, age, primary language spoken and whether the woman
had undergone HIV testing in the past. We conducted an
intention-to-treat analysis using CONSORT guidelines, including
recommendations on reporting of non-inferiority randomized
trials. [13,14]
Sample Size
Our sample size calculation was based on the primary outcome,
decisional conflict score. Because this was a non-inferiority trial,
the trial was designed to be able to exclude an actual difference
between the abbreviated and standard counseling arms of greater
than 5.625 (the non-inferiority margin) with respect to the mean
decisional conflict score (DCS) in each group. To calculate our
sample size we selected a non-inferiority margin of 5.625 based on
investigator judgment of a likely clinically significant difference in
DCS. We used a type-I error rate (alpha) of 0.05 with an 80%
power, a common standard deviation of 18.75 for the DCS
obtained from pilot testing of the DCS instrument, and a one-
sided two group t-test of equivalence in means (equal n’s) to arrive
at 139 patients in each arm for a total of 278 participants. [15,16]
Results
Between October 3, 2006 and September 24, 2007, study staff
approached 496 pregnant patients initiating prenatal care at the
Women’s Health Center at San Francisco General Hospital to
participate in the study. We excluded 215 patients from
participation in the study. See Figure 1. Of the 281 women
randomized to one of the study arms, 3 women were discontinued
from the study and excluded from the analysis because they were
identified as being ineligible only after randomization. In all 3
cases, the women had been tested for HIV during the index
pregnancy prior to the initial prenatal visit at SFGH.
Two hundred seventy eight women were eligible and random-
ized – 134 (48.2%) in the abbreviated arm (AA) and 144 (51.8%)
in the standard arm (SA). Women in the 2 groups were similar at
baseline, with no statistically significant differences in age, race/
ethnicity, primary language, type of provider, prior HIV testing
history, and time since prior HIV test. See Table 2.
There was no significant difference in the proportion of women
with low decisional conflict (71.6% in AA vs. 76.4% in SA, p=.37)
See Table 3. Likewise, there were no significant differences in
mean DCS scores (mean 19.9 in abbreviated vs. 16.0 in standard
arm, p=.17) and the observed mean difference between the
groups of 3.88 (95% CI: 20.65, 8.41) did not statistically exceed
the non-inferiority margin. There were no differences in DCS
scores when stratifying by primary language spoken, ethnicity, age,
and prior HIV testing. (Data not shown.) Similarly, women in the
2 arms expressed similar overall satisfaction with their decision to
test or not test for HIV (97.8% in AA vs. 99.3% in SA, p=.36).
On the other hand, women in AA had significantly lower mean
and median knowledge scores (mean=78.4%) compared to
women in SA (mean=83.7%, p,0.01). In particular, knowledge
scores were significantly lower among women in AA who were
Spanish-speakers, Latina, $ 27 years old or had undergone HIV
testing in the past. (Data not shown.) In comparing the 9
knowledge items individually, the only question that women in the
standard arm were significantly more likely to answer correctly
related to the decreased risk of perinatal HIV transmission
through the use of antiretroviral medication during pregnancy.
(Data not shown.)
Overall testing uptake was very high (97.8%) and did not differ
significantly between the 2 groups (99.3% in AA vs. 96.5% in SA,
p=.12). The most common reason given for testing was ‘‘it’s a
good idea to have it as a routine test’’ (90.4%). Other reasons given
included: ‘‘concerned about my own health’’ (86.0%), ‘‘concerned
about risks to the baby’’ (81.2%), ‘‘because it was offered’’ (80.8%)
and ‘‘clinic staff thought it was a good idea’’ (67.2%). There were
no significant differences in the reasons given by women between
the two groups. See Table 4. There were 6 women in our sample
who decided not to take the HIV test. The reasons given included:
‘‘been in a stable relationship for a long time’’ (n=1 AA; n=4
SA), ‘‘partner has been tested elsewhere’’ (n=1 AA; n=3 SA),
‘‘tested negative before’’ (n=1 AA; n=3 SA), ‘‘not in a high risk
group’’ (n=2 SA) and ‘‘not necessary, as I have no chance of
being positive’’ (n=2 SA).
Of the 278 women enrolled, 247 (89%) returned for a follow-up
visit and completed the post-disclosure questionnaire (median time
to follow-up visit=2.7 weeks). Overall, 11.2% of women enrolled
in the study were lost to clinical follow-up between initial prenatal
visit and medical follow-up visit, 13 women in the abbreviated arm
(9.7%) and 18 women in the standard arm (12.5%). At the time of
the follow-up survey, all but one participant reported feeling glad
about their decision to test or not test (100% in AA vs. 99.2% in
SA, p=.33). The only woman reporting not feeling glad about her
testing decision was one of the 6 study participants who had not
undergone testing. Among the women who responded they were
glad about their decision regarding testing, 2 (0.8%) were women
who had decided not to take the test. There were no significant
differences among women in the 2 arms reporting their comfort
waiting for test results (91.7% in AA vs. 91.1% in SA, p=.85) as
well as stating they knew as much about HIV/AIDS as they
wanted to (74.4% in AA vs. 77.8% in SA, p=.53) and had their
questions related to HIV answered (97.5% in AA vs. 95.1% in SA,
p=.32).
Discussion
This study suggests that streamlining the pre-test consenting
process, while associated with lower knowledge, does not
compromise patient decision making or satisfaction regarding
HIV testing. Studies in Scotland have shown that provider-
performed HIV counseling and testing is associated with increased
uptake of HIV testing in the perinatal setting and is equally
acceptable as testing strategies involving passive HIV testing
education. [17] Moreover, a cross-sectional study of English and
Spanish-speaking prenatal patients found that nearly 70% of
Pretest HIV Counseling Trial
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should be given this test’’) as compared to 27% who supported
‘‘elective’’ testing (‘‘only on women who want it and who give their
permission to have the test’’). [18] This support for routine
prenatal HIV testing was comparable to these women’s attitudes
towards routine rubella screening (63%) and routine gonorrhea/
chlamydia screening (77%). While the O’Connor Decisional
Conflict Scale has been used in studies evaluating a vast range
of health decisions from breast cancer treatment and autologous
pre-donation in cardiac surgery to PSA screening, [9,19–25][9,19–
25] we know of only one other study utilizing this scale to assess
patient perspectives on HIV testing. [26] In this study of 46
pregnant women undergoing rapid HIV testing on Labor and
Delivery at our institution, we found that 89% of the women
reported feeling satisfied with their testing experience, and 82.6%
of women reported no decisional conflict (score#25) in making
decisions for rapid testing, similar to what was seen in this current
study.
While knowledge scores were statistically significantly lower
among women randomized to the abbreviated study arm,
knowledge scores were overall high among women in both arms
of the trial. The overall high scores were notable and reassuring
given the ethnic diversity and low literacy of our clinic population.
[27,28] The difference in knowledge scores was driven primarily by
Figure 1. Flow Diagram Legend. * Women who were excluded for ‘‘other reasons’’ included women who initially consented to participate in the
study but then changed their mind prior to undergoing the questionnaire.
# Women who received the Standard instead of the Abbreviated consent
due to nurse ‘‘error’’.
@ Women were discontinued from study after pre-test survey completed and they were excluded from the analysis. They were
identified as being ineligible only after randomization and administration of pre-test survey.
doi:10.1371/journal.pone.0005166.g001
Pretest HIV Counseling Trial
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infectedpregnantwomencantakemedicationtodecreasetheriskof
perinatal HIV transmission. As more institutions and prenatal
practices institute the CDC recommended abbreviated HIV pre-
test counseling, our data identify gaps in knowledge among low-
income, ethnically-diverse pregnant patients and may assist in
guiding population-level campaigns that will likely replace the one-
on-one pre-test counseling session as a source of patient education.
Table 2. Baseline Characteristics (n=278)
Abbreviated Standard p-value
(n=134) (n=144)
Median age in years (range) 26.0 (17–38) 26.0 (16–42) .57 *
Ethnicity, No. (%)
White 8 (6.0) 16 (11.1)
Black 23 (17.2) 19 (13.2)
Hispanic/Latina 84 (62.7) 98 (68.1) .15
#
Asian/Pacific Islander 18 (13.4) 11 (7.6)
Mixed/Other 1 (0.7) 0 (0)
Primary Language, No. (%)
English 62 (46.3) 63 (43.8) .67
Spanish 72 (53.7) 81 (56.3)
Provider Type, No. (%)
Midwife 82 (61.2) 96 (66.7)
Nurse Practitioner 13 (9.7) 10 (6.9) .57
Physician 39 (29.1) 38 (26.4)
Prior HIV testing, No. (%) 80 (59.7) 94 (65.3) .34
Median # months since prior HIV test (range) 24.0 (0.6–169.1) 17.7 (1.3–176.7) .17 *
Self-perceived likeliness of HIV infection: Median (range)@ 5.0 (1–5) 5.0 (1–5) .81 *
*Wilcoxon Mann-Whitney test
#Fisher’s Exact Test
@Self-perceived likeliness of HIV infection based on 5 point Liekert scale 1=very likelyR5=very unlikely [14]
doi:10.1371/journal.pone.0005166.t002
Table 3. Decisional conflict, satisfaction, knowledge and testing uptake
Abbreviated Standard p-value
n=134 (48.2) n=144 (51.8)
Decisional Conflict Score, No. (%)
[95% Confidence Interval]
Low DCS (#25) 96 110 .37
(71.6%) (76.4%)
[64.0–79.3] [69.5–83.3]
High DCS (.25) 38 34
(28.4%) (23.6%)
[20.7–36.0] [16.7–30.5]
Mean Decisional Conflict Score (SD) 19.9 (21.0) 16.0 (17.4) .17
[95% Confidence Interval] [16.3–23.5] [13.1–18.9]
Median Decisional Conflict Score (range) 10.0 (0–90) 10.0 (0–70)
Mean knowledge score (SD) 78.4 (15.5) 83.7 (13.2 ) ,.01
[95% Confidence Interval] [75.7–81.0] [81.5–85.9]
Median knowledge score (range) 77.8 (11.1–100.0) 88.9 (44.4–100.0)
Testing Uptake, No. (%) 133 139 .12
(99.3) (96.5)
[95% Confidence Interval] [97.8–100] [93.5–99.5]
doi:10.1371/journal.pone.0005166.t003
Pretest HIV Counseling Trial
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study staff, standardized protocols and validated instruments, our
study had limitations. As with most surveys assessing patient
satisfaction and perceptions, participants may have been biased
towards reporting positive attitudes towards testing and limited
decisional conflict, despite reassurances about confidentiality of
responses and the use of blinded study staff. The slight, though
statistically insignificant, higher mean decisional conflict score seen
among women in the abbreviated arm suggest that responses may
indeed have been truthful. While we did not monitor in real time
the nurses administering the standard and abbreviated counseling
scripts, we utilized standardized protocols and scripts and trained
the nurses during study implementation and conducted on-going
education to the nurses about study protocols. Nonetheless, there
may have been deviations from the assigned consenting script that
went unnoticed. Moreover, efforts to optimize the uptake of
prenatal HIV testing in this clinical setting were instituted prior to
initiation of this study even with the use of more traditional
standard pre-test counseling by nurses as we have reported
elsewhere. [29] Given the very high acceptance of prenatal HIV
testing under non-study conditions at our clinic, our results may
not be generalizable to other clinical settings with lower baseline
uptake of HIV testing. Similarly, our results may not be
generalizable to areas with less developed HIV educational and
public health campaigns as compared to San Francisco. Lastly,
participants were, by definition, willing to give additional time and
effort to participate in this research. As such, participants may
have differed in significant and clinically relevant ways from non-
participants. In particular, participants may have been more
agreeable to health interventions as compared to non-participants
and, thus, may have biased the data toward increased satisfaction
and minimized the differences between the 2 arms of the study.
This bias may also limit the generalizability of our results to
populations of pregnant women who would not otherwise
participate in research. While selection bias may limit the
generalizability of our results, study participation was very high
– only 14.5% of women approached for enrollment refused to
participate.
Despite these potential limitations, this study adds to the
growing body of literature evaluating best practices in integrating
routine HIV testing into medical settings. While there were no
differences seen in testing uptake in our study, this streamlined
approach to pretest consenting would likely facilitate the
systematic implementation the CDC guidelines recommending
universal HIV testing of pregnant women. As such, abbreviated
HIV testing strategies may be associated with increased HIV
testing uptake on a population level without jeopardizing patients’
decision-making process. There are numerous states in the U.S.
that still require detailed pre-test counseling and consenting prior
to prenatal HIV testing. [30] These data support the elimination
of such requirements and should bolster legislative efforts to
update HIV testing laws aimed at decreasing the burden on
health-care providers and reducing overall barriers to HIV testing.
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